31
Participants
Start Date
September 27, 2018
Primary Completion Date
October 23, 2019
Study Completion Date
October 23, 2019
GDC-0853
Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Renstar Medical Research, Ocala
Clinical Research Center of Alabama, LLC, Birmingham
Vital Prospects Clinical Research Institute PC - CRN, Tulsa
Allergy & Asthma Immunology Associates, Scottsdale
Integrated Research Group Inc, Riverside
Southern California Research Center, Mission Viejo
Kern Allergy Med Clinic, Inc., Bakersfield
Allergy & Asthma Consultants, Redwood City
Asthma, Nasal Disease, and Allergy Research Center of New England, East Providence
Timber Lane Allergy and Asthma Research, LLC, Burlington
Lead Sponsor
Genentech, Inc.
INDUSTRY